Most roundups of weight-loss telehealth act like everyone is trying to drop 15 pounds before a wedding. When you’re carrying 50, 80, or 100-plus pounds to lose, the calculus is completely different. You need sustained medication access, not a one-month trial. You need a provider that won’t disappear after the FDA’s next compounding crackdown. And you need pricing that doesn’t bankrupt you over a two-year process.
Here’s what I actually found after sorting through the noise.
1. HealthRX
Price alone almost disqualifies most telehealth programs for a long haul. HealthRX starts compounded semaglutide at $99 a month and compounded tirzepatide at $149, which is genuinely lower than most cash-pay competitors at the same entry tier. For someone staring down 18 to 24 months of treatment, that gap adds up fast.
What I actually care about beyond price: the pharmacy behind the medication. HealthRX dispenses through Manifest Pharmacy, a 503A-accredited compounder in Greer, South Carolina, operating under USP-797 standards with lot-tracked batches from mixing to delivery. That’s a named, auditable facility, not a mystery lab. LegitScript certified (certificate 50087439), which means an independent party has verified its legitimacy. Free overnight shipping to all 50 states. A board-certified physician reads through your intake form and responds within about a day.
The clinical data HealthRX references comes from published trials, not its own marketing. Tirzepatide showed approximately 21% body weight reduction at 72 weeks in SURMOUNT-1. Semaglutide showed roughly 15% at 68 weeks in STEP 1. Those are the benchmarks.
One honest note: these are compounded medications, not FDA-approved products. That distinction matters and you should understand it going in.
For the long-haul, high-BMI patient on a budget, this is where I’d start.
2. FormBlends
FormBlends occupies a specific niche that most GLP-1 telehealth ignores entirely. It publishes per-product purity testing. HPLC purity figures, mass spectrometry identity confirmation, endotoxin and sterility results, with actual numbers attached. For people who’ve read about compounding quality issues and want documentation before injecting anything, that transparency is genuinely rare.
Pricing is higher than HealthRX, compounded semaglutide around $299 and tirzepatide around $349. So you’re paying a premium. It ships to 47 states rather than all 50. Same clinician-oversight model, same 503A pharmacy framework.
The added angle: FormBlends runs a broader peptide catalog alongside its GLP-1 line, covering recovery, longevity, and cognitive compounds, all under the same physician model. If you want one provider managing multiple peptide protocols while you’re on a GLP-1, this is the only option on this list that offers that.
I’d pick FormBlends over HealthRX for someone who prioritizes published batch documentation or wants to bundle GLP-1 treatment with other peptide therapies. For pure price-per-month value on a 50-plus-pound loss process, HealthRX still wins.
3. Mochi Health
Mochi uses board-certified obesity-medicine physicians, which matters clinically when you have significant weight to lose and potential comorbidities. Monthly costs run approximately $99 for compounded semaglutide and around $199 for compounded tirzepatide. More monitoring than some budget options. A solid mid-tier choice if you want specialty-trained oversight without paying Form Health prices.
4. Ro Body
Ro’s prior-authorization team actively works insurance approvals for branded medications. If you have coverage that could realistically approve Wegovy or Zepbound, that’s worth the $39 first-month fee. Ongoing membership runs $74 to $149, with meds billed separately. For long-term patients with good insurance, the total cost can come out below any cash-pay option.
5. Hims & Hers
After exiting compounded GLP-1 following the March 2026 Novo settlement, Hims & Hers shifted to branded medications only. Injectable Wegovy is around $299 a month, oral options around $249, Zepbound around $399. With insurance and a savings card, some patients reportedly pay under $25. Big brand infrastructure. No compounded product anymore, which removes certain concerns but adds cost.
6. Henry Meds
Fast. Henry Meds ships compounded product within 24 to 72 hours of approval, which is faster than most. Your first month is typically billed somewhere in the $179 to $249 range. Lighter on monitoring than Mochi or Form Health. Good option when speed and low friction matter more than intensive check-ins.
7. Found
Found charges about $99 a month for platform access plus medication costs separately. It includes coaching alongside the prescription piece. Reasonable mid-range option for people who want behavioral support built in rather than a pure prescription service.
8. Form Health
The premium end of this category. Form Health pairs an MD with a registered dietitian, charges around $299 a month plus labs and medication costs. For someone with a complex metabolic history or multiple conditions alongside obesity, that dual-clinician model might be worth every dollar. For someone otherwise healthy who just needs sustained GLP-1 access, it’s probably more infrastructure than necessary.
A Few Things Worth Knowing
The FDA sent warning letters to more than 30 telehealth and compounding companies in early 2026. That regulatory pressure is real. Verify that any provider you choose uses a named, credentialed compounding pharmacy before you commit.
Lilly’s oral orforglipron became available through LillyDirect around April 2026 at approximately $149 a month, which changes the branded-vs-compounded math for some patients.
None of the programs above are a substitute for a conversation with your own doctor, especially if you have cardiovascular or kidney conditions.
Common Questions
How long do you actually need to stay on a GLP-1 program when you have 50 or more pounds to lose?
Most clinical trials ran 68 to 72 weeks, and that’s roughly where the headline weight-loss numbers come from. In practice, people with 50-plus pounds to lose often need 18 to 30 months of active treatment, followed by a maintenance conversation with their provider. Stopping early typically leads to significant regain.
Is compounded semaglutide or tirzepatide safe to use for a year or longer?
Compounded versions use the same active molecule as branded products, but they aren’t FDA-approved and quality depends entirely on the pharmacy producing them. For long-term use, the pharmacy’s accreditation and batch testing documentation matter more than the brand name on the vial. Ask specifically for 503A or 503B status before committing.
Which of these programs is most likely to still have compounded product available a year from now, given the FDA’s 2026 crackdowns?
No program can guarantee future compounding access, honestly. That said, providers using established 503A pharmacies with LegitScript certification and named facilities, like HealthRX through Manifest Pharmacy, are better positioned than those relying on anonymous compounders. The regulatory risk is real for everyone in this space.
If I have type 2 diabetes alongside obesity, does that change which program I should choose?
Yes, meaningfully. Diabetes adds clinical complexity that a basic async telehealth intake may not handle well. Mochi Health’s obesity-medicine physicians and Form Health’s MD-plus-dietitian model are better equipped for patients managing both conditions. Your A1c and kidney function should factor into medication selection, and a generalist platform may miss that.
Does the cost difference between HealthRX at $149 and FormBlends at $349 for tirzepatide actually reflect a quality difference?
The price gap reflects transparency and breadth, not necessarily a purity difference. FormBlends publishes HPLC and mass spectrometry results per batch. HealthRX doesn’t publish equivalent documentation publicly. Both use 503A pharmacies. If documented batch testing gives you confidence over a long treatment course, the $200 monthly premium may be worth it. If you’re primarily focused on sustained affordability, it probably isn’t.
Sources
- SURMOUNT-1 trial (tirzepatide): published in *The New England Journal of Medicine*, 2022
- STEP 1 trial (semaglutide): published in *The New England Journal of Medicine*, 2021
- FDA compounding warning letters, early 2026: FDA.gov public announcements
- Novo Nordisk settlement announcement, March 9 2026: Reuters and Novo investor disclosures
- LegitScript pharmacy certification database: LegitScript.com (public search)
- Lilly orforglipron / LillyDirect launch pricing: Eli Lilly press release, April 2026
